Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$22.01 +0.5%	$21.21	$13.40 ▼ $25.23	$3.66B	0.64	1.98 million shs	2.57 million shs
RNA Avidity Biosciences	$31.70 -5.6%	$30.61	$21.51 ▼ $56.00	$4.05B	0.91	1.40 million shs	2.12 million shs
SWTX SpringWorks Therapeutics	$46.99	$46.69	$28.21 ▼ $62.00	$3.54B	0.68	2.62 million shs	N/A
ZYME Zymeworks	$12.88 -3.5%	$12.30	$9.03 ▼ $17.70	$897.52M	1.19	578,242 shs	325,366 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.55%	+4.71%	+1.38%	+51.06%	+22.07%
RNA Avidity Biosciences	-5.57%	+8.38%	+1.05%	+23.06%	-30.51%
SWTX SpringWorks Therapeutics	0.00%	0.00%	+0.45%	+24.51%	+12.31%
ZYME Zymeworks	-3.52%	-0.54%	+1.66%	+14.49%	+25.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.5676 of 5 stars	4.4	3.0	2.7	4.2	2.5
RNA Avidity Biosciences	2.3209 of 5 stars	4.5	0.0	3.2	0.8	0.0
SWTX SpringWorks Therapeutics	1.5968 of 5 stars	3.1	2.0	2.7	0.0	0.6
ZYME Zymeworks	3.039 of 5 stars	3.5	4.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	26.65% Upside
RNA Avidity Biosciences	3.06	Buy	$66.35	109.32% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	11.88% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.00	63.04% Upside

Current Analyst Ratings Breakdown

Latest ZYME, SWTX, RNA, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	RNA Avidity Biosciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
7/10/2025	RNA Avidity Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$55.00
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00
6/27/2025	RNA Avidity Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$96.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/24/2025	RNA Avidity Biosciences	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$50.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.85	$0.74 per share	29.76	$4.40 per share	5.00
RNA Avidity Biosciences	$8.93M	427.97	N/A	N/A	$11.94 per share	2.65
SWTX SpringWorks Therapeutics	$191.59M	18.48	N/A	N/A	$6.47 per share	7.26
ZYME Zymeworks	$93.38M	9.61	N/A	N/A	$6.63 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	16.07	28.96	4.52	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$258.13M	-$3.41	N/A	N/A	N/A	-115.60%	-51.10%	-43.80%	8/6/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.49	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	7/30/2025 (Estimated)

Latest ZYME, SWTX, RNA, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	RNA Avidity Biosciences	-$0.93	N/A	N/A	N/A	$1.61 million	N/A
8/7/2025	N/A	ZYME Zymeworks	-$0.52	N/A	N/A	N/A	$17.18 million	N/A
8/6/2025	Q2 2025	SWTX SpringWorks Therapeutics	-$0.81	N/A	N/A	N/A	$73.39 million	N/A
8/5/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/8/2025	N/A	ZYME Zymeworks	-$0.45	-$0.30	+$0.15	N/A	$20.65 million	$27.11 million
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
RNA Avidity Biosciences	N/A	16.91	16.91
SWTX SpringWorks Therapeutics	N/A	4.33	4.18
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
RNA Avidity Biosciences	N/A
SWTX SpringWorks Therapeutics	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
RNA Avidity Biosciences	3.83%
SWTX SpringWorks Therapeutics	7.83%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	120.00 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	69.45 million	Optionable
ZYME Zymeworks	460	69.68 million	67.56 million	Optionable

ZYME, SWTX, RNA, and ACAD Headlines

Recent News About These Companies

ZYME | Zymeworks Inc. Annual Cash Flow Statement | MarketWatch

July 11, 2025 | marketwatch.com

Bispecific Antibody Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

July 9, 2025 | finance.yahoo.com

Zymeworks (NYSE:ZYME) Receives "Neutral" Rating from HC Wainwright

July 5, 2025 | americanbankingnews.com

Zymeworks (NYSE:ZYME) Given "Neutral" Rating at HC Wainwright

July 3, 2025 | marketbeat.com

Zymeworks Amends Warrant Agreement with EcoR1 Capital

June 27, 2025 | tipranks.com

ZYME - Zymeworks Inc Registered Shs Dividends - Morningstar

June 27, 2025 | morningstar.comM

Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth

June 25, 2025 | finance.yahoo.com

Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy

June 20, 2025 | zacks.com

Rhumbline Advisers Has $985,000 Stock Position in Zymeworks Inc. (NYSE:ZYME)

June 20, 2025 | marketbeat.com

Duncan Williams Asset Management LLC Buys Shares of 22,095 Zymeworks Inc. (NYSE:ZYME)

June 19, 2025 | marketbeat.com

Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500

June 18, 2025 | kalkinemedia.comK

SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME)

June 17, 2025 | marketbeat.com

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

June 12, 2025 | seekingalpha.com

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?

June 4, 2025 | zacks.com

Zymeworks’ zanidatamab gains approval in China for biliary tract cancer

June 2, 2025 | msn.com

Roche’s 96-week data for multiple sclerosis drug; ZymeWorks claims $20M milestone

May 30, 2025 | endpts.comE

China's NMPA Approves Zymeworks' Ziihera for HER2-High Biliary Tract Cancer

May 30, 2025 | precisionmedicineonline.comP

Zymeworks’ zanidatamab approved in China

May 30, 2025 | thepharmaletter.comT

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge

May 30, 2025 | msn.com

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 30, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off

ZYME, SWTX, RNA, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$22.01 +0.12 (+0.55%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$22.13 +0.12 (+0.55%)

As of 07/15/2025 05:44 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Avidity Biosciences NASDAQ:RNA

$31.70 -1.87 (-5.57%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$32.00 +0.30 (+0.95%)

As of 07/15/2025 07:55 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

SpringWorks Therapeutics NASDAQ:SWTX

$46.99 0.00 (0.00%)

As of 07/1/2025

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Zymeworks NYSE:ZYME

$12.88 -0.47 (-3.52%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$12.86 -0.02 (-0.16%)

As of 07/15/2025 04:24 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time